Sanjay Sethi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7568613/publications.pdf

Version: 2024-02-01

184	12,836	22132	24961
papers	citations	59 h-index	109 g-index

188	188	188	9563
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population. International Journal of COPD, 2022, Volume 17, 593-608.	0.9	10
2	Pseudomonas aeruginosa Colonization and COPD: The Chicken or the Egg?. Archivos De Bronconeumologia, 2022, 58, 539-541.	0.4	10
3	Proteomic Network Analysis of Bronchoalveolar Lavage Fluid in Ex-Smokers to Discover Implicated Protein Targets and Novel Drug Treatments for Chronic Obstructive Pulmonary Disease. Pharmaceuticals, 2022, 15, 566.	1.7	5
4	Response to the Letter to the Editor Regarding â€œIntraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studiesâ€•[Response to Letter]. International Journal of COPD, 2021, Volume 16, 1227-1229.	0.9	0
5	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1251-1258.	2.5	121
6	Association of Chronic Lower Respiratory Disease With County Health Disparities in New York State. JAMA Network Open, 2021, 4, e2134268.	2.8	0
7	Revefenacin for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2020, 14, 239-247.	1.0	0
8	Treatment of Acute Exacerbations in Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2020, 41, 439-451.	0.8	7
9	Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies . International Journal of COPD, 2020, Volume 15, 2889-2900.	0.9	14
10	Chronic Obstructive Pulmonary Disease in the Intensive Care Unit: Antibiotic Treatment of Severe Chronic Obstructive Pulmonary Disease Exacerbations. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 830-841.	0.8	5
11	Oralâ€lung microbiome interactions in lung diseases. Periodontology 2000, 2020, 83, 234-241.	6.3	97
12	Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies. Respiratory Research, 2020, 21, 128.	1.4	4
13	Novel Use of Home Pulse Oximetry Monitoring in COVIDâ€19 Patients Discharged From the Emergency Department Identifies Need for Hospitalization. Academic Emergency Medicine, 2020, 27, 681-692.	0.8	127
14	Enhanced Drug and Device Development by Targeting â€œRelief of Dyspneaâ€• Chest, 2020, 158, 464-466.	0.4	2
15	Prediction model development of women's daily asthma control using fitness tracker sleep disruption. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 548-555.	0.8	4
16	Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662090527.	1.0	3
17	Impact of Pseudomonas aeruginosa Isolation on Mortality and Outcomes in an Outpatient Chronic Obstructive Pulmonary Disease Cohort. Open Forum Infectious Diseases, 2020, 7, ofz546.	0.4	33
18	Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology, 2020, 13, 103-113.	1.3	1

#	Article	IF	Citations
19	Antibiotic Retreatment for Acute Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 481-482.	2.5	1
20	Hacking the Immune Response to Infection in Chronic Obstructive Pulmonary Disease. , 2020, , .		1
21	Validation of fitness tracker for sleep measures in women with asthma. Journal of Asthma, 2019, 56, 719-730.	0.9	10
22	Compartmentalization of anti-oxidant and anti-inflammatory gene expression in current and former smokers with COPD. Respiratory Research, 2019, 20, 190.	1.4	16
23	Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?. European Respiratory Journal, 2019, 54, 1901405.	3.1	0
24	Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease. Data in Brief, 2019, 26, 104277.	0.5	1
25	Bacterial regulation of macrophage bacterial recognition receptors in COPD are differentially modified by budesonide and fluticasone propionate. PLoS ONE, 2019, 14, e0207675.	1.1	10
26	Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials. Pulmonary Pharmacology and Therapeutics, 2019, 57, 101808.	1.1	11
27	Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. Respiratory Medicine, 2019, 153, 38-43.	1.3	25
28	AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD . International Journal of COPD, 2019, Volume 14, 667-682.	0.9	24
29	Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD . International Journal of COPD, 2019, Volume 14, 2947-2958.	0.9	6
30	Acute exacerbations in chronic obstructive pulmonary disease: should we use antibiotics and if so, which ones?. Current Opinion in Infectious Diseases, 2019, 32, 143-151.	1.3	17
31	Early Hospital Readmissions after an Acute Exacerbation of Chronic Obstructive Pulmonary Disease in the Nationwide Readmissions Database. Annals of the American Thoracic Society, 2018, 15, 837-845.	1.5	84
32	Future Research Directions in Pneumonia. NHLBI Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 256-263.	2.5	54
33	Haemophilus influenzae genome evolution during persistence in the human airways in chronic obstructive pulmonary disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3256-E3265.	3.3	57
34	Increased Fisherâ€™s information for parameters of association in count regression via extreme ranks. Communications in Statistics - Theory and Methods, 2018, 47, 1181-1203.	0.6	2
35	Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	4
36	Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. International Journal of COPD, 2018, Volume 14, 117-127.	0.9	2

#	Article	IF	Citations
37	Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1268-1278.	2.5	60
38	To Improve COPD Care. Chest, 2018, 154, 235-237.	0.4	5
39	Lower Airway Bacterial Colonization Patterns and Species-Specific Interactions in Chronic Obstructive Pulmonary Disease. Journal of Clinical Microbiology, 2018, 56, .	1.8	22
40	Reply: Looking for Predictors of Early Readmission in Chronic Obstructive Pulmonary Disease: Every Effort Is Required. Annals of the American Thoracic Society, 2018, 15, 1367-1367.	1.5	0
41	Interpreting Recent Developments in COPD Treatments. Journal of Family Practice, 2018, 67, S33-S39.	0.2	0
42	The microbiome in respiratory medicine: current challenges and future perspectives. European Respiratory Journal, 2017, 49, 1602086.	3.1	194
43	Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. Chest, 2017, 151, 340-357.	0.4	91
44	A randomised, placebo-controlled trial of antiâ€“interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease. Respiratory Research, 2017, 18, 153.	1.4	71
45	IL-18 associated with lung lymphoid aggregates drives IFNÎ³ production in severe COPD. Respiratory Research, 2017, 18, 159.	1.4	28
46	Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspensionâ„¢ Delivery Technology Versus ForadilÂ® AerolizerÂ® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 21-33.	0.5	5
47	Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β₂-agonist fixed-dose combination: RE²SPOND rationale and study design. International Journal of COPD, 2016, Volume 11, 1921-1928.	0.9	9
48	Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspensionâ„¢ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD. Respiratory Research, 2016, 17, 109.	1.4	16
49	A Sputum Proteomic Signature That Associates with Increased IL-1Î² Levels and Bacterial Exacerbations of COPD. Lung, 2016, 194, 363-369.	1.4	22
50	Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. Antimicrobial Agents and Chemotherapy, 2016, 60, 4151-4158.	1.4	26
51	<scp>COPD</scp> and the microbiome. Respirology, 2016, 21, 590-599.	1.3	130
52	Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting Î²₂-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE²SPOND). A Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 559-567.	2.5	109
53	The Impact of Exogenous Factors on Respiratory Pathogen-Induced Innate Alveolar Macrophage Responses in COPD. Immunological Investigations, 2016, 45, 130-147.	1.0	5
54	The lung microbiome and exacerbations of COPD. Current Opinion in Pulmonary Medicine, 2016, 22, 196-202.	1.2	50

#	Article	IF	Citations
55	Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial. PLoS ONE, 2016, 11, e0163716.	1.1	92
56	Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD. International Journal of COPD, 2015, 10, 985.	0.9	6
57	IL-17A and the Promotion of Neutrophilia in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 428-437.	2.5	95
58	Expression of IgA Proteases byHaemophilus influenzaein the Respiratory Tract of Adults With Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2015, 212, 1798-1805.	1.9	29
59	Calcium Restores the Macrophage Response to Nontypeable Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2015, 52, 728-737.	1.4	15
60	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, e4-e27.	2.5	166
61	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Journal, 2015, 45, 879-905.	3.1	138
62	C-Reactive Protein at Discharge, Diabetes Mellitus and â‰¥1 Hospitalization During Previous Year Predict Early Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 311-320.	0.7	23
63	Impaired Innate COPD Alveolar Macrophage Responses and Toll-Like Receptor-9 Polymorphisms. PLoS ONE, 2015, 10, e0134209.	1.1	18
64	Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials. Respiratory Research, 2014, 15, 124.	1.4	91
65	T-Regulatory Cells and Programmed Death 1⁺ T Cells Contribute to Effector T-Cell Dysfunction in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 40-50.	2.5	110
66	Performance of the EXAcerbations of Chronic Pulmonary Disease Tool Patient-reported Outcome Measure in Three Clinical Trials of Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2014, 11, 316-325.	1.5	41
67	Bacterial Colonization Increases Daily Symptoms in Patients with Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2014, 11, 303-309.	1.5	93
68	The reliability and validity of patient-reported chronic obstructive pulmonary disease exacerbations. Current Opinion in Pulmonary Medicine, 2014, 20, 146-152.	1.2	8
69	A 5-day course of systemic corticosteroids is adequate to treat acute exacerbations of chronic obstructive pulmonary disease. Evidence-Based Medicine, 2014, 19, 57-57.	0.6	2
70	Role of Infections. Clinics in Chest Medicine, 2014, 35, 87-100.	0.8	40
71	Chronic Obstructive Pulmonary Disease and Infection. Disruption of the Microbiome?. Annals of the American Thoracic Society, 2014, 11, S43-S47.	1.5	13
72	Long-term macrolide therapy in chronic obstructive pulmonary disease. Cmaj, 2014, 186, 1148-1152.	0.9	14

#	Article	IF	Citations
73	Infections in â€œNoninfectiousâ€•Lung Diseases. Annals of the American Thoracic Society, 2014, 11, S221-S226.	1.5	8
74	Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations. Thorax, 2014, 69, 811-818.	2.7	83
75	Airway Microbiome Dynamics in Exacerbations of Chronic Obstructive Pulmonary Disease. Journal of Clinical Microbiology, 2014, 52, 2813-2823.	1.8	272
76	Large-Scale, Ion-Current-Based Proteomics Investigation of Bronchoalveolar Lavage Fluid in Chronic Obstructive Pulmonary Disease Patients. Journal of Proteome Research, 2014, 13, 627-639.	1.8	59
77	Systemic Inflammation in Predicting COPD Exacerbations. JAMA - Journal of the American Medical Association, 2013, 309, 2390.	3.8	7
78	Design and validation of a supragenome array for determination of the genomic content of Haemophilus influenzae isolates. BMC Genomics, 2013, 14, 484.	1.2	14
79	Antibiotics for treatment and prevention ofÂexacerbations of chronic obstructive pulmonary disease. Journal of Infection, 2013, 67, 497-515.	1.7	69
80	Phagocytic Dysfunction of Human Alveolar Macrophages and Severity of Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2013, 208, 2036-2045.	1.9	106
81	Infectious Mechanisms Regulating Susceptibility to Acute Exacerbations of COPD. , 2013, , 159-176.		0
82	Chance Favors the Prepared Mind. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1070-1071.	2.5	1
83	Pseudomonas infection in chronic obstructive pulmonary disease. Future Microbiology, 2012, 7, 1129-1132.	1.0	29
84	Significance of the microbiome in obstructive lung disease. Thorax, 2012, 67, 456-463.	2.7	190
85	Moxifloxacinversusamoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. European Respiratory Journal, 2012, 40, 17-27.	3.1	68
86	Surveillance Cultures in Respiratory Tract Infections. Chest, 2012, 141, 577-578.	0.4	0
87	Inflammation in COPD: Implications for Management. American Journal of Medicine, 2012, 125, 1162-1170.	0.6	86
88	Personalised medicine in exacerbations of COPD: the beginnings. European Respiratory Journal, 2012, 40, 1318-1319.	3.1	6
89	Acute Exacerbations of Chronic Obstructive Pulmonary Disease. , 2012, , 183-186.		0
90	Targeting Nrf2 Signaling Improves Bacterial Clearance by Alveolar Macrophages in Patients with COPD and in a Mouse Model. Science Translational Medicine, 2011, 3, 78ra32.	5.8	271

#	Article	IF	Citations
91	Nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease and lung cancer. International Journal of COPD, 2011, 6, 113.	0.9	74
92	A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology. International Journal of COPD, 2011, 6, 373.	0.9	11
93	Effects of Bacterial Infection on Airway Antimicrobial Peptides and Proteins in COPD. Chest, 2011, 140, 611-617.	0.4	54
94	Bronchodilator Combination Therapy for the Treatment of Chronic Obstructive Pulmonary Disease. Current Clinical Pharmacology, 2011, 6, 48-61.	0.2	10
95	Standardizing Measurement of Chronic Obstructive Pulmonary Disease Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 323-329.	2.5	160
96	Human Models of Exacerbations of COPD. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 691-692.	2.5	5
97	The benefits of long-term systemic antimicrobial therapy in chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease, 2011, 5, 207-216.	1.0	4
98	Characterizing and Quantifying the Symptomatic Features of COPD Exacerbations. Chest, 2011, 139, 1388-1394.	0.4	71
99	Molecular Diagnosis of Respiratory Tract Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Clinical Infectious Diseases, 2011, 52, S290-S295.	2.9	42
100	Molecular Basis of Increased Serum Resistance among Pulmonary Isolates of Non-typeable Haemophilus influenzae. PLoS Pathogens, 2011, 7, e1001247.	2.1	82
101	A Clonal Group of Nontypeable Haemophilus influenzae with Two IgA Proteases Is Adapted to Infection in Chronic Obstructive Pulmonary Disease. PLoS ONE, 2011, 6, e25923.	1.1	30
102	Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): A Patient-Reported Outcome (PRO) Measure. Value in Health, 2010, 13, 965-975.	0.1	97
103	Antibiotic Resistance in Sputum Isolates ofStreptococcus pneumoniaein Chronic Obstructive Pulmonary Disease is Related to Antibiotic Exposure. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2010, 7, 337-344.	0.7	28
104	Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respiratory Research, 2010, 11, 10.	1.4	155
105	Antibiotics in acute exacerbations of chronic bronchitis. Expert Review of Anti-Infective Therapy, 2010, 8, 405-417.	2.0	5
106	Bacteria Challenge in Smoke-exposed Mice Exacerbates Inflammation and Skews the Inflammatory Profile. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 666-675.	2.5	104
107	New Paradigms in the Pathogenesis of Chronic Obstructive Pulmonary Disease II. Proceedings of the American Thoracic Society, 2009, 6, 532-534.	3.5	58
108	Use of Moraxella catarrhalis Lipooligosaccharide Mutants To Identify Specific Oligosaccharide Epitopes Recognized by Human Serum Antibodies. Infection and Immunity, 2009, 77, 4548-4558.	1.0	13

#	Article	IF	Citations
109	Identification of Domains of the Hag/MID Surface Protein Recognized by Systemic and Mucosal Antibodies in Adults with Chronic Obstructive Pulmonary Disease following Clearance of Moraxella catarrhalis. Vaccine Journal, 2009, 16, 653-659.	3.2	19
110	Moraxella catarrhalisacquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease. BMC Infectious Diseases, 2009, 9, 178.	1.3	48
111	Pseudomonas aeruginosaPopulation Biology in Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2009, 200, 1928-1935.	1.9	67
112	Epitope mapping immunodominant regions of the PilA protein of nontypeable Haemophilus influenzae (NTHI) to facilitate the design of two novel chimeric vaccine candidates. Vaccine, 2009, 28, 279-289.	1.7	52
113	The problems of meta-analysis for antibiotic treatment of chronic obstructive pulmonary disease, a heterogeneous disease: a commentary on Puhan et al. BMC Medicine, 2008, 6, 29.	2.3	5
114	Infection in the Pathogenesis and Course of Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2008, 359, 2355-2365.	13.9	1,046
115	COPD as a Lung Disease with Systemic Consequences â€“ Clinical Impact, Mechanisms, and Potential for Early Intervention. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 235-256.	0.7	240
116	Serial Isolates of Persistent Haemophilus influenzae in Patients with Chronic Obstructive Pulmonary Disease Express Diminishing Quantities of the HMW1 and HMW2 Adhesins. Infection and Immunity, 2008, 76, 4463-4468.	1.0	22
117	Pseudomonas aeruginosa in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 853-860.	2.5	253
118	Inflammatory Profile of New Bacterial Strain Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 491-497.	2.5	156
119	Bacterial Load and Exacerbations of COPD. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1049-1049.	2.5	1
120	Optimizing antibiotic selection in treating COPD exacerbations. International Journal of COPD, 2008, Volume 3, 31-44.	0.9	38
121	Serum Antipneumococcal Antibodies and Pneumococcal Colonization in Adults with Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2007, 196, 928-935.	1.9	28
122	Airway Bacterial Concentrations and Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 356-361.	2.5	174
123	Exacerbations of Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2007, 4, 554-564.	3.5	135
124	Haemophilus haemolyticus:A Human Respiratory Tract Commensal to Be Distinguished fromHaemophilus influenzae. Journal of Infectious Diseases, 2007, 195, 81-89.	1.9	205
125	Bronchoscopic Valor in Exacerbations of Chronic Bronchitis. Journal of Bronchology, 2007, 14, 137-139.	0.2	0
126	Pathogenesis of Bacterial Exacerbations of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2006, 3, 109-115.	0.7	55

#	Article	IF	Citations
127	Airway Inflammation and Bronchial Bacterial Colonization in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 991-998.	2.5	331
128	Role of nontypeable Haemophilus Influenzae in exacerbations and progression of chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine, 2006, 12, 118-124.	1.2	57
129	Coinfection in Exacerbations of COPD. Chest, 2006, 129, 223-224.	0.4	17
130	Human serum and mucosal antibody responses to outer membrane protein G1b ofMoraxella catarrhalisin chronic obstructive pulmonary disease. FEMS Immunology and Medical Microbiology, 2006, 46, 139-146.	2.7	16
131	Impaired Alveolar Macrophage Response toHaemophilusAntigens in Chronic Obstructive Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 31-40.	2.5	92
132	Modulation of Airway Inflammation by Haemophilus influenzae Isolates Associated with Chronic Obstructive Pulmonary Disease Exacerbation. Proceedings of the American Thoracic Society, 2006, 3, 482-483.	3.5	11
133	Impaired Phagocytosis of NontypeableHaemophilus influenzaeby Human Alveolar Macrophages in Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2006, 194, 1375-1384.	1.9	197
134	Differential Genome Contents of Nontypeable Haemophilus influenzae Strains from Adults with Chronic Obstructive Pulmonary Disease. Infection and Immunity, 2006, 74, 3366-3374.	1.0	43
135	Impact of Acute Exacerbations on the Natural History of Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine, 2005, 12, S16-S18.	0.3	2
136	Expression of a peroxiredoxinÃ¢Â€Â“glutaredoxin byHaemophilus influenzaein biofilms and during human respiratory tract infection. FEMS Immunology and Medical Microbiology, 2005, 44, 81-89.	2.7	51
137	Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitis. Annals of Clinical Microbiology and Antimicrobials, 2005, 4, 5.	1.7	14
138	Outer Membrane Protein P6 of Nontypeable Haemophilus influenzae Is a Potent and Selective Inducer of Human Macrophage Proinflammatory Cytokines. Infection and Immunity, 2005, 73, 2728-2735.	1.0	67
139	Pathogenesis and Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 192-203.	0.8	22
140	Are ColonialHaemophilus influenzaeResponsible for Exacerbations of Chronic Obstructive Pulmonary Disease After All?. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 194-195.	2.5	0
141	Haemophilus influenzaefrom Patients with Chronic Obstructive Pulmonary Disease Exacerbation Induce More Inflammation than Colonizers. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 85-91.	2.5	139
142	RSV Infection â€" Not for Kids Only. New England Journal of Medicine, 2005, 352, 1810-1812.	13.9	18
143	Moraxella catarrhalisin Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 195-199.	2.5	247
144	Human Antibody Response to Outer Membrane Protein G1a, a Lipoprotein of Moraxella catarrhalis. Infection and Immunity, 2005, 73, 6601-6607.	1.0	18

#	Article	IF	Citations
145	Efficacy and Safety of Pharmacokinetically Enhanced Amoxicillin-Clavulanate at 2,000/125 Milligrams Twice Daily for 5 Days versus Amoxicillin-Clavulanate at 875/125 Milligrams Twice Daily for 7 Days in the Treatment of Acute Exacerbations of Chronic Bronchitis. Antimicrobial Agents and Chemotherapy, 2005, 49, 153-160.	1.4	32
146	Antigenic Specificity of the Mucosal Antibody Response to Moraxella catarrhalis in Chronic Obstructive Pulmonary Disease. Infection and Immunity, 2005, 73, 8161-8166.	1.0	47
147	Identification of Surface Antigens of Moraxella catarrhalis as Targets of Human Serum Antibody Responses in Chronic Obstructive Pulmonary Disease. Infection and Immunity, 2005, 73, 3471-3478.	1.0	43
148	Moxifloxacin for the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Clinical Infectious Diseases, 2005, 41, S177-S185.	2.9	14
149	Managing patients with recurrent acute exacerbations of chronic bronchitis: a common clinical problem. Current Medical Research and Opinion, 2004, 20, 1511-1521.	0.9	9
150	Persistent Colonization byHaemophilus influenzaein Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 266-272.	2.5	270
151	Strain-specific Immune Response toHaemophilus influenzaein Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 448-453.	2.5	139
152	Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiologyâ€"impact on approaches to risk stratification and therapy. Infectious Disease Clinics of North America, 2004, 18, 861-882.	1.9	26
153	Bacteria in Exacerbations of Chronic Obstructive Pulmonary Disease: Phenomenon or Epiphenomenon?. Proceedings of the American Thoracic Society, 2004, 1, 109-114.	3.5	119
154	New developments in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease. Current Opinion in Infectious Diseases, 2004, 17, 113-119.	1.3	54
155	The role of antibiotics in acute exacerbations of chronic obstructive pulmonary disease. Current Infectious Disease Reports, 2003, 5, 9-15.	1.3	10
156	Gatifloxacin in community-acquired respiratory tract infection. Expert Opinion on Pharmacotherapy, 2003, 4, 1847-1855.	0.9	1
157	Human Immune Response to Outer Membrane Protein CD of Moraxella catarrhalis in Adults with Chronic Obstructive Pulmonary Disease. Infection and Immunity, 2003, 71, 1288-1294.	1.0	34
158	Horizontal Transfer of the Gene Encoding Outer Membrane Protein P2 of NontypeableHaemophilus influenzae,in a Patient with Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2003, 188, 114-117.	1.9	27
159	New Strains of Bacteria and Exacerbations of Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2002, 347, 465-471.	13.9	931
160	Systemic and Mucosal Antibody Response toMoraxella catarrhalisafter Exacerbations of Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2002, 185, 632-640.	1.9	54
161	Sequence Stability of the Gene Encoding Outer Membrane Protein P2 of NontypeableHaemophilus influenzaein the Human Respiratory Tract. Journal of Infectious Diseases, 2002, 185, 627-631.	1.9	29
162	INFLAMMATORY MARKERS IN BACTERIAL EXACERBATIONS OF COPD. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 132-132.	2.5	10

#	Article	IF	Citations
163	Lymphocyte Proliferative Response to P6 ofHaemophilus influenzaeIs Associated with Relative Protection from Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 967-971.	2.5	72
164	Chronic Obstructive Pulmonary Disease. Drugs and Aging, 2002, 19, 761-775.	1.3	55
165	Bacterial pneumonia. Managing a deadly complication of influenza in older adults with comorbid disease. Geriatrics, 2002, 57, 56-61.	0.3	13
166	Acute Exacerbations of Chronic Bronchitis. Drugs and Aging, 2001, 18, 1-11.	1.3	24
167	Diagnosis and treatment of upper respiratory tract infections in the primary care setting. Clinical Therapeutics, 2001, 23, 1683-1706.	1.1	46
168	Bacterial Infection in Chronic Obstructive Pulmonary Disease in 2000: a State-of-the-Art Review. Clinical Microbiology Reviews, 2001, 14, 336-363.	5.7	493
169	Inflammation and Acute Exacerbations of Chronic Bronchitis. Chest, 2001, 120, 1423.	0.4	0
170	Bacteria and COPD Exacerbations Redux. Chest, 2001, 119, 666-667.	0.4	0
171	The Role of Bacteria in Exacerbations of COPD. Chest, 2000, 118, 204-209.	0.4	106
172	Infectious Etiology of Acute Exacerbations of Chronic Bronchitis. Chest, 2000, 117, 380S-385S.	0.4	243
173	Bacterial Infection and the Pathogenesis of COPD. Chest, 2000, 117, 286S-291S.	0.4	146
174	Airway Inflammation and Etiology of Acute Exacerbations of Chronic Bronchitis. Chest, 2000, 118, 1557-1565.	0.4	196
175	Simultaneous Respiratory Tract Colonization by Multiple Strains of NontypeableHaemophilus influenzaein Chronic Obstructive Pulmonary Disease: Implications for Antibiotic Therapy. Journal of Infectious Diseases, 1999, 180, 404-409.	1.9	91
176	Infectious exacerbations of chronic bronchitis: diagnosis and management. Journal of Antimicrobial Chemotherapy, 1999, 43, 97-105.	1.3	77
177	Etiology and Management of Infections in Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine, 1999, 6, 327-332.	0.3	18
178	Analysis of Antigenic Structure and Human Immune Response to Outer Membrane Protein CD of Moraxella catarrhalis. Infection and Immunity, 1999, 67, 4578-4585.	1.0	36
179	MANAGEMENT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS. Infectious Diseases in Clinical Practice, 1998, 7, S300-S308.	0.1	9
180	Human Immune Response to NontypeableHaemophilus influenzaein Chronic Bronchitis. Journal of Infectious Diseases, 1997, 176, 1247-1252.	1.9	63

#	Article	IF	Citations
181	Outer membrane protein CD of Branhamella catarrhalis: Sequence conservation in strains recovered from the human respiratory tract. Microbial Pathogenesis, 1995, 19, 215-225.	1.3	42
182	Bacterial Infection in Chronic Obstructive Pulmonary Disease. The American Review of Respiratory Disease, 1992, 146, 1067-1083.	2.9	486
183	What is bacterial colonisation in COPD?. , 0, , 161-171.		1
184	Bacterial infection. , 0, , 97-113.		1